LOS ANGELES, CA - July 7, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.
Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) deals, highlighting continued strategic investment in differentiated antibody platforms.
The Novartis transaction follows a series of major antibody therapeutics deals, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.
For VERAXA shareholders, the Novartis-Myricx deal is a further validation of the value of novel ADC platforms. VERAXA’s BiTAC technology is designed to enable both bispecific T cell engagers and bispecific ADCs, offering versatility that could appeal to large pharma partners seeking to enhance their oncology pipelines. The company’s pipeline includes candidates that leverage its proprietary BiTAC format, which has the potential to overcome key challenges in solid tumor targeting and payload delivery.
As the biotech industry continues to see high-value transactions in the ADC space, VERAXA’s focus on differentiated antibody therapeutics positions it as a potential acquisition target or partner for companies looking to expand their capabilities. The company’s technology was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
Forward Looking Statements: Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. For more information, see the company's filings with the SEC. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Please see full disclaimers at http://IBN.fm/Disclaimer.
